CYP-002 is under clinical development by Cynata Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CYP-002’s likelihood of approval (LoA) and phase transition for Osteoarthritis took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 08 May 2021 increased CYP-002’s LoA and PTSR for Cytokine Release Syndrome (Cytokine Storm).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CYP-002 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CYP-002 overview

CYP-002 is under development for the treatment of critical limb ischemia, cytokine release syndrome, asthma, osteoarthritis, myocardial infarction, ventricular arrhythmia and coronary heart disease. The stem cell therapy is a regenerative medicine therapy consisting of mesenchymoangioblast which is a common precursor for both mesenchymal stem cells (MSCs) and endothelial cells. This stem cell therapy incorporates Cymerus platform stem cell technology. It is administered through intramuscular route.

Cynata Therapeutics overview

Cynata Therapeutics is a stem cell and regenerative medicine company. It develops and commercializes Cymerus, a stem cell platform technology used for the production of mesenchymal stem cells (MSCs) for human therapeutic use. Its proprietary technology platform utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor for generating mesenchymoangioblasts (MCAs) in manufacturing the Cymerus MSC therapeutic products for the treatment of osteoarthritis, brain cancer and melanoma, Crohn’s disease, asthma, acute respiratory distress syndrome and heart attack. Its lead MSC product candidate CYP-001 is used for the prevention and treatment of Graft-versus-host-disease (GvHD). The company has operations in Ireland and, the US. Cynata Therapeutics is headquartered in Carlton, Australia.

Quick View CYP-002 LOA Data

Report Segments
  • Innovator
Drug Name
  • CYP-002
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Cardiovascular
  • Immunology
  • Musculoskeletal Disorders
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.